<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900276</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00000577</org_study_id>
    <secondary_id>P30CA012197</secondary_id>
    <secondary_id>CCCWFU-89A06</secondary_id>
    <secondary_id>CCCWFU-IRB00000577</secondary_id>
    <nct_id>NCT00900276</nct_id>
  </id_info>
  <brief_title>Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants</brief_title>
  <official_title>BARC: A Secreted Marker of Kidney Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy&#xD;
      participants in the laboratory may help doctors identify and learn more about biomarkers&#xD;
      related to cancer.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at biomarkers in patients with kidney cancer or&#xD;
      cancer of the urothelium and in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether bone morphogenetic protein antagonist regulated in cancer (BARC) is&#xD;
           present in urine and serum samples from patients with renal cell carcinoma or&#xD;
           transitional cell carcinoma of the urothelium and from healthy participants and whether&#xD;
           changes in BARC expression levels in these fluids correlate with various disease states.&#xD;
&#xD;
        -  Evaluate BARC's utility as a biomarker of kidney cancer.&#xD;
&#xD;
        -  Determine whether differences in BARC levels exist between patients with cancer vs&#xD;
           non-cancer patients visiting the urology clinic.&#xD;
&#xD;
        -  Determine whether differences in BARC levels exist among the different types of kidney&#xD;
           cancers.&#xD;
&#xD;
        -  Evaluate serum markers of iron metabolism and determine whether changes in BARC&#xD;
           expression correlates with changes in these systemic iron markers.&#xD;
&#xD;
        -  Determine whether the development of an enzyme-linked immunosorbent assay to detect BARC&#xD;
           levels as a diagnostic procedure is feasible and desirable.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Blood and urine samples are collected. Samples are evaluated by immunoblotting to detect bone&#xD;
      morphogenetic protein antagonist regulated in cancer (BARC) and by mass spectrometry analysis&#xD;
      to detect hepcidin levels. Serum samples are further analyzed for serum iron, ferritin, and&#xD;
      total-iron body capacity. Histology of biopsy samples will be recorded for patients&#xD;
      undergoing nephrectomy for renal cell carcinoma. These patients will undergo a second&#xD;
      collection of blood and urine samples 3 months post-nephrectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of bone morphogenetic protein antagonist regulated in cancer (BARC) in urine and serum samples</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>BARC expression levels</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of changes in serum markers of iron metabolism with changes in BARC expression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of an enzyme-linked immunosorbent assay to detect BARC levels as a diagnostic procedure</measure>
  </primary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <condition>Urethral Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Those with a diagnosis of renal cell carcinoma or a diagnosis of transitional cell&#xD;
        carcinoma of the urothelium.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Diagnosis of renal cell carcinoma, meeting all of the following criteria:&#xD;
&#xD;
                    -  Suitable surgical candidate&#xD;
&#xD;
                    -  No clinical or pathologic T stage &gt; T2&#xD;
&#xD;
                    -  No clinical or pathologic evidence of vein and/or lymph node involvement&#xD;
&#xD;
                    -  No evidence of metastatic disease as evaluated by abdominal/pelvic CT scan&#xD;
                       or MRI, chest x-ray or chest CT scan, and bone scan (if alkaline phosphatase&#xD;
                       abnormal)&#xD;
&#xD;
               -  Diagnosis of transitional cell carcinoma of the urothelium&#xD;
&#xD;
                    -  Currently undergoing Bacille calmette-gu√©rin (BCG) therapy OR has not&#xD;
                       received prior BCG therapy&#xD;
&#xD;
               -  Healthy participant (control)&#xD;
&#xD;
                    -  No history of carcinoma&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Previous or concurrent malignancy except curatively treated carcinoma in situ of the&#xD;
             cervix or nonmelanoma skin cancer&#xD;
&#xD;
          -  Serious medical or psychiatric illness that would preclude study compliance&#xD;
&#xD;
          -  Current participation in a treatment related research study within the last 30 days&#xD;
&#xD;
          -  Acute illness&#xD;
&#xD;
          -  Bleeding disorder or dyscrasia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank M. Torti, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>recurrent transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>regional transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>stage I renal cell cancer</keyword>
  <keyword>stage II renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <keyword>stage II bladder cancer</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>anterior urethral cancer</keyword>
  <keyword>posterior urethral cancer</keyword>
  <keyword>recurrent urethral cancer</keyword>
  <keyword>urethral cancer associated with invasive bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

